Palatin Technologies (NYSEAMERICAN:PTN) Releases Earnings Results, Beats Estimates By $0.26 EPS

Share on StockTwits

Palatin Technologies (NYSEAMERICAN:PTN) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.26, Fidelity Earnings reports. The company had revenue of $60.27 million for the quarter.

NYSEAMERICAN PTN opened at $1.06 on Friday. Palatin Technologies has a 1 year low of $0.59 and a 1 year high of $1.78.

In other Palatin Technologies news, major shareholder Stephen T. Wills bought 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were bought at an average cost of $25.31 per share, with a total value of $37,965.00. Also, insider Carl Spana bought 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was acquired at an average cost of $0.86 per share, for a total transaction of $43,000.00. Following the completion of the purchase, the insider now directly owns 5,953,852 shares of the company’s stock, valued at $5,120,312.72. The disclosure for this purchase can be found here. Insiders purchased 74,880 shares of company stock worth $101,008 over the last three months.

A number of research analysts have recently issued reports on PTN shares. LADENBURG THALM/SH SH set a $3.00 price objective on Palatin Technologies and gave the company a “buy” rating in a research note on Thursday, May 23rd. Zacks Investment Research cut Palatin Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, HC Wainwright set a $8.00 price objective on Palatin Technologies and gave the company a “buy” rating in a research note on Monday, June 24th.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.

Recommended Story: Dividend Achievers

Earnings History for Palatin Technologies (NYSEAMERICAN:PTN)

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Circassia Pharmaceuticals  Rating Reiterated by Peel Hunt
Circassia Pharmaceuticals Rating Reiterated by Peel Hunt
Baader Bank Analysts Give SAP  a €120.00 Price Target
Baader Bank Analysts Give SAP a €120.00 Price Target
Sartorius  Given a €184.00 Price Target by UBS Group Analysts
Sartorius Given a €184.00 Price Target by UBS Group Analysts
US Capital Advisors Comments on Centennial Resource Development Inc’s Q3 2019 Earnings
US Capital Advisors Comments on Centennial Resource Development Inc’s Q3 2019 Earnings
Q3 2019 Earnings Estimate for Delphi Technologies PLC  Issued By Jefferies Financial Group
Q3 2019 Earnings Estimate for Delphi Technologies PLC Issued By Jefferies Financial Group
Associated Banc  to Release Earnings on Thursday
Associated Banc to Release Earnings on Thursday


 
© 2006-2019 Zolmax.